Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.48 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.48 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.45 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.43 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.42 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.42 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.42 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.42 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.42 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4463331 | 0.83 | CACNA2D1 (0.47) | TPSAB1TPSD1TPSG1HTTCACNA2D1 | |
| SCHEMBL4457633 | 0.80 | CACNA2D1 (0.45) | CACNA2D1CACNB1CACNA1CCACNA1BLMNA | |
| SCHEMBL4557152 | 0.77 | KCNA3 (0.43) | — | |
| SCHEMBL4462451 | 0.73 | CACNA2D1 (0.53) | HTTCACNA2D1CACNB1CACNA1CCACNA1B | |
| SCHEMBL7714059 | 0.70 | KDM4D (0.45) | — | |
| SCHEMBL7714056 | 0.70 | KDM4D (0.45) | — | |
| SCHEMBL8282230 | 0.70 | CACNA2D1 (0.44) | HTTAGTR2CACNA2D1CACNB1CACNA1C | |
| SCHEMBL22148074 | 0.68 | SLC6A9 (0.42) | HPGDRAB9ACYP2D6 | |
| SCHEMBL4463788 | 0.68 | DPP4 (0.46) | CYP3A4RAB9ACYP2D6TDP1 | |
| SCHEMBL16874734 | 0.68 | ALDH1A1 (0.40) | HPGDRAB9ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | claimed |
| JP-2007518742-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1718633-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-11-08 | — | — | EP | claimed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | claimed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | claimed |
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| US-7507760-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-03-24 | — | — | US | disclosed |
| EP-1718633-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | disclosed |
| WO-2005070919-A1 | N-TYPE CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2005-08-04 | — | — | WO | disclosed |
| US-20050165065-A1 | N-type calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165065-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1D | TPSAB1 825/4885TPSD1 1237/4885TPSG1 2730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.